FDA's enforcement report carries a Class II recall, dated 14 October 2026, of compounded tirzepatide 26 mg/mL in single-use syringes from Carolina Infusion, for lack of assurance of sterility linked to the use of bacteriostatic water and to processing equipment. It sits among a group of related recalls from the same firm covering other compounded tirzepatide and semaglutide strengths, some combined with cyanocobalamin. The recall is listed as ongoing.
This is a quality action on compounded batches, not a finding about tirzepatide itself. For prescribers it is a reminder that compounded incretin products are not the licensed pens and that their sterility, strength and stability depend on the compounder.
- Ask patients on tirzepatide or semaglutide whether they use a licensed pen or a compounded product.
- Consider injection-site or systemic infection in a patient using compounded injectables who develops fever or skin changes.
- Compounded products may differ in strength from licensed ones; check dose and response if switching.
- Report suspected adverse events from compounded products to the national regulator.
Why it matters
Patients and prescribers often cannot tell a compounded syringe from a licensed pen without asking.
Don't overread it
This is a sterility recall of specific compounded batches, not a safety signal about tirzepatide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free